The use of Monte Carlo simulation to predict vancomycin dosage for methicillin-resistant Staphylococcus aureus in Thai patients of various ages and with varying degrees of renal function

[1]Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009; 34:473–83.10.1111/j.1365-2710.2008.01016.x19583681YamamotoMKuzuyaTBabaHYamadaKNabeshimaT.Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease typeJ Clin Pharm Ther.20093447383Open DOISearch in Google Scholar

[2]Sánchez JL, Dominguez AR, Lane JR, Anderson PO, Capparelli EV, Cornejo-Bravo JM. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010; 48:525–33.10.5414/CPP4852520650044SánchezJLDominguezARLaneJRAndersonPOCapparelliEVCornejo-BravoJM.Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approachesInt J Clin Pharmacol Ther.20104852533Open DOISearch in Google Scholar

[3]Revilla N, Martin-Suárez A, Pérez MP, González FM, Fernández de Gatta Mdel M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol. 2010; 70:201–12.10.1111/j.1365-2125.2010.03679.x20653673RevillaNMartin-SuárezAPérezMPGonzálezFMFernández de Gatta MdelM.Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulationBr J Clin Pharmacol.20107020112Open DOISearch in Google Scholar

[4]Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982; 21:575–80.708197810.1128/AAC.21.4.575BlouinRABauerLAMillerDDRecordKEGriffenWO Jr.Vancomycin pharmacokinetics in normal and morbidly obese subjectsAntimicrob Agents Chemother.19822157580Search in Google Scholar

[5]Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984; 25:433–7.10.1128/AAC.25.4.4336732213MatzkeGRMcGoryRWHalstensonCEKeaneWF.Pharmacokinetics of vancomycin in patients with various degrees of renal functionAntimicrob Agents Chemother.1984254337Open DOISearch in Google Scholar

[6]Purwonugroho TA, Chulavatnatol S, Preechagoon Y, Chindavijak B, Malathum K, Bunuparadah P. Population pharmacokinetics of vancomycin in Thai patients. ScientificWorldJournal. 2012; 2012:762649. 10.1100/2012/762649.22547995PurwonugrohoTAChulavatnatolSPreechagoonYChindavijakBMalathumKBunuparadahP.Population pharmacokinetics of vancomycin in Thai patientsScientificWorldJournal.2012201276264910.1100/2012/762649Open DOISearch in Google Scholar

[7]Canut A, Isla A, Betriu C, Gascón AR. Pharmacokinetic–pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis. 2012; 31:2227–35.2237129410.1007/s10096-012-1560-7CanutAIslaABetriuCGascónAR.Pharmacokinetic–pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countriesEur J Clin Microbiol Infect Dis.201231222735Search in Google Scholar

[8]Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014; 44:235–41.10.1016/j.ijantimicag.2014.05.01225052866HousmanSTSutherlandCANicolauDP.Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitalsInt J Antimicrob Agents.20144423541Open DOISearch in Google Scholar

[9]Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect. 2008; 14:116–23.1807667210.1111/j.1469-0691.2007.01885.xKutiJLKifferCRVMendesCMFNicolauDP.Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in BrazilClin Microbiol Infect.20081411623Search in Google Scholar

[10]Mei Q, Ye Y, Zhu YL, Cheng J, Yang HF, Liu YY, et al. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2015; 45:652–56.10.1016/j.ijantimicag.2015.01.01825813394MeiQYeYZhuYLChengJYangHFLiuYYUse of Monte Carlo simulation to evaluate the development of vancomycin resistance in methicillin-resistant Staphylococcus aureusInt J Antimicrob Agents.20154565256Open DOISearch in Google Scholar

[11]Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925–42.10.2165/00003088-200443130-0000515509186Moise-BroderPAForrestABirminghamMCSchentagJJ.Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsClin Pharmacokinet.20044392542Open DOISearch in Google Scholar

[12]Bonate PL. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet. 2001; 40:15–22.1123680710.2165/00003088-200140010-00002BonatePL.A brief introduction to Monte Carlo simulationClin Pharmacokinet.2001401522Search in Google Scholar

[13]Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011; 66:227–31.10.1093/jac/dkq44921118912RobertsJAKirkpatrickCMLipmanJ.Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patientsJ Antimicrob Chemother.20116622731Open DOISearch in Google Scholar

[14]Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49:507–14.1958641310.1086/600884LodiseTPPatelNLomaestroBMRodvoldKADrusanoGL.Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patientsClin Infect Dis.20094950714Search in Google Scholar

[15]Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: a retrospective analysis. Ann Pharmacother. 2012; 46:1477–83.10.1345/aph.1R158HoreyAMergenhagenKAMattappallilA.The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: a retrospective analysisAnn Pharmacother.201246147783Open DOISearch in Google Scholar

[16]Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr., Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66:82–98.10.2146/ajhp080434RybakMLomaestroBRotschaferJCMoelleringR Jr.CraigWBilleterMTherapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsAm J Health Syst Pharm.2009668298Open DOISearch in Google Scholar

[17]Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006; 42 Suppl 1:S35–9.1632311810.1086/491712RybakMJ.The pharmacokinetic and pharmacodynamic properties of vancomycinClin Infect Dis.2006421S359Search in Google Scholar

[18]Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008; 52:3315–20.10.1128/AAC.00113-0818591266LodiseTPGravesJEvansAGraffunderEHelmeckeMLomaestroBMRelationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycinAntimicrob Agents Chemother.200852331520Open DOISearch in Google Scholar

[19]Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012; 68:1243–55.2241163010.1007/s00228-012-1259-9ElyasiSKhaliliHDashti-KhavidakiSMohammadpourA.Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature reviewEur J Clin Pharmacol.201268124355Search in Google Scholar

[20]Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents. 2011; 37:202–9.2130052810.1016/j.ijantimicag.2010.10.030GouldIMCaudaREspositoSGudiolFMazzeiTGarauJ.Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits?Int J Antimicrob Agents.2011372029Search in Google Scholar

[21]Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003; 36:1418–23.1276683710.1086/375057LodiseTPMcKinnonPSSwiderskiLRybakMJ.Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremiaClin Infect Dis.200336141823Search in Google Scholar

[22]Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51:1089–91.1715894110.1128/AAC.00671-06TsujiBTRybakMJLauKLSakoulasG.Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureusAntimicrob Agents Chemother.200751108991Search in Google Scholar